Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV-BR-1-GM Vaccine in Advanced Breast Cancer
NCT00095862Phase 2Terminated
- Sponsor
- Wiseman Research Initiatives
- Start
- Nov 2004
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SV-BR-1-GM in breast cancer and solid tumor, sponsored by Wiseman Research Initiatives. Primary endpoints: Safety, tolerability, and feasibility, Clinical response and 3 more. Started Nov 2004; status: terminated.
02
Drugs
SV-BR-1-GM
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT00095862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095862.